CEO J.D. Finley promised that the biotech is “in the midst of encouraging discussions that we believe will lead to pipeline expansion opportunities in high value indications in the GI space.” ...

However, investors were disappointed and the stock fell following the announcement ... to GSK’s growing portfolio in gastrointestinal (GI) cancers, including ongoing trials with dostarlimab ...

Often, they aren't profitable or even generating revenue, which can normally be the case when it comes to biotech stocks. Vera Therapeutics (VERA) is a biotech stock that falls into that category.

Pipeline and key clinical candidates for these companies: Galmed is a clinical stage biopharmaceutical company focused on the development of Aramchol for liver and fibro-inflammatory diseases.

So if you're looking to make a relatively small investment of $1,000 in one stock that's on the riskier side, it's hard to park your cash in a more exciting and upwardly mobile biotech than Viking.

After a rough start to the year, biotech stocks have been on an upswing, standing out in a difficult market for high-growth stocks. These notoriously volatile names have outperformed the broad ...

Investors' deep pessimism is actually bullish, and less regulatory constraint could fuel new drug approval and M&A Biotech is one of the U.S. stock market's most unloved sectors. But several ...

and there are still more than 100 biotech stocks worth less than the cash they have in the bank. Yet there are also very clear signs that the worst might be over for the sector. For investors with ...

Novo Nordisk looks to harness Septerna’s broader GPCR drug pathways, which include GLP-1, for obesity and diabetes treatments ...

It was an extremely busy week in the biotech sector, with several companies ... The acquisition adds to GSK’s growing portfolio in gastrointestinal (GI) cancers, including ongoing trials with ...